{"data":{"id":"us-ok/okla.-stat.-tit.-63-63-5026","jurisdiction":"us-ok","citation":"Okla. Stat. tit. 63, § 63-5026","heading":"Medicaid prescription drug program – Definition of","body":"phenylketonuria.\n\nA. The Oklahoma Health Care Authority Board shall, in\n\nadministering the Medicaid prescription drug program, utilize the\n\nfollowing definition for \"phenylketonuria\" to mean: An inborn error\n\nof metabolism attributable to a deficiency of or a defect in\n\nphenylalanine hydroxylase, the enzyme that catalyzes the conversion\n\nof phenylalanine to tyrosine. The deficiency permits the\n\naccumulation of phenylalanine and its metabolic products in the body\n\nfluids. The deficiency can result in intellectual disabilities\n\n(phenylpyruvic oligophrenia), neurologic manifestations (including\n\nhyperkinesia, epilepsy, and microcephaly), light pigmentation, and\n\neczema. The disorder is transmitted as an autosomal recessive trait\n\nand can be treated by administration of a diet low in phenylalanine.\n\nB. The Oklahoma Health Care Authority Board shall promulgate\n\nany rules necessary to effectuate the provisions of this section.","path":["OK Code","Title 63"],"source_url":"https://www.oklegislature.gov/OK_Statutes/CompleteTitles/os63.pdf","current_through":"2026-08-14","vintage":"open-us-law v2026.08, retrieved 2026-09-14","retrieved_at":"2026-09-14T18:32:36Z","sha256":"be7bbb915eb53b5421e1fe265f9befe815223181084ffe2cc07693d18542291f","source_id":"us-ok","stale":false,"prev":"us-ok/okla.-stat.-tit.-63-63-5025","next":"us-ok/okla.-stat.-tit.-63-63-5026.1"},"notice":"GroundRules: Original legal text. Not legal advice."}